Methylene Blue.
Boosts brain energy & memory Acts like a power-up for your mitochondria, the energy generators in your cells. Helps your brain make more energy (ATP), which can improve memory and focus.
Reviewed March 2026
- Category
- Compound
- Also filed under
- Cognitive EnhancementMitochondrial SupportNeuroprotectionAntioxidant Support
What Methylene Blue is, and what it does.
- Does it work
- Yes, for experienced users who do their homework. The evidence for mitochondrial support is strong. Human memory studies are promising but small. Not for beginners.
- How much to take
- Start low. 5-10mg per day. Some go up to 20mg. More is not better here; high doses can have the opposite effect.
- Time to feel it
- It absorbs within an hour or two and colours urine blue or green the same day. Reports of steadier mental clarity come after one to two weeks of low daily use.
- The first dose
- Your urine will turn blue or green within hours. That's how you know it's working. Some people feel a slight mental lift, but for most it's subtle at first.
- With regular use
- After a week or two, many report sustained mental clarity and less brain fog. It works in the background to keep your brain's energy systems running smoothly.
- How well tolerated
- Well tolerated at low doses IF you get pure USP grade and aren't on SSRIs. The antidepressant interaction is the biggest red flag. The aquarium stuff is poison for humans.
- How it feels
- Not a stimulant. It's a clear, calm focus. Like your brain is just working better, without the forced push of caffeine.
- The overlooked benefit
- It works in both directions on the redox scale: an electron shuttle at low concentrations, an oxidant generator higher up. That curve is why the small daily amounts are the studied ones.
5 to 20mg a day is where Methylene Blue works.
Source: Rodriguez et al., Br J Pharmacol, 2014; Rojas et al., Neurobiol Aging, 2012
The proof, claim by claim.
These words describe the research, not the molecule's worth. Research strength is how much work stands behind one claim, and it is never a product score.
Mechanisms of action in the mitochondria are well-proven. Human evidence for memory enhancement exists but is limited to smaller trials compared to its extensive animal research.
- Improves short-term memorySmall RCTs & fMRI studies
- Increases mitochondrial ATP productionIn-vitro & Animal studies
- NeuroprotectionAnimal models
Questions people ask about Methylene Blue.
- Why does my pee turn blue?
- That's the compound being flushed out. It's a harmless, expected side effect and proof you absorbed it.
- Is this the same stuff used for fish tanks?
- No. Absolutely not. Fish tank grade is full of heavy metals and contaminants. Only use USP pharmaceutical grade made for humans.
- Can I take this with my antidepressant (Prozac, Zoloft)?
- NO. This is a hard stop. It can cause a dangerous condition called serotonin syndrome. Do not mix them.
- Will it make me feel wired like caffeine?
- Nope. It's a different feeling. More like mental clarity and endurance, not a jittery energy spike.
- Do I need to cycle it?
- Many people do. A common protocol is 5 days on, 2 days off to maintain sensitivity. It's not strictly required but often recommended.
- Best time to take it?
- Morning. It's about energy production, so taking it before bed isn't the best idea.
Why these belong in the same formula. Each row says what the basis is, from settled biochemistry through to a trial that measured the pair.
Methylene blue is a potent inhibitor of monoamine oxidase A, the enzyme that clears serotonin, while 5-HTP is the precursor the body converts straight into serotonin. Feeding more raw material while slowing the main breakdown route can raise serotonin signaling well beyond what either does on its own, so this is a pairing to keep apart rather than stack.
The monoamine oxidase that methylene blue blocks also breaks down the catecholamines, dopamine and noradrenaline, that the body builds from L-tyrosine. Adding a catecholamine precursor on top of that enzyme block can let catecholamine tone climb more than intended, which is why the two are treated with caution together.
Ascorbate reduces methylene blue to its colourless leuco form, and the leuco form is reoxidised again, which is the classic redox cycle taught with this dye. Co-dosing changes which oxidation state predominates rather than simply adding two antioxidants.
Methylene blue inhibits monoamine oxidase A, so serotonin is cleared more slowly. Adding its dietary precursor pushes serotonin synthesis up at the same time clearance is down, and the two should not be stacked.
5-HTP is decarboxylated straight to serotonin, and methylene blue slows the enzyme that breaks serotonin down. Combining a precursor with a clearance blocker raises serotonergic signalling more than either does alone.
St John's wort constituents slow serotonin reuptake while methylene blue slows its enzymatic breakdown. Two different brakes on the same transmitter pool should not be applied together.
SAM-e raises monoamine turnover as a methyl donor in transmitter synthesis, and methylene blue reduces monoamine oxidase A activity. The combination pushes serotonergic tone from both sides.
Methylene blue accepts electrons from NADH and hands them onward, which is how it acts as an alternative carrier around a slow point in the chain. The size of the NAD and NADH pool sets how much of that cycling can happen.
NMN raises cellular NAD, the carrier methylene blue shuttles electrons from at low doses. More carrier means more capacity for that cycling step.
NR is converted to NMN and then NAD, the pool that supplies the electrons methylene blue carries. The pairing supports the carrier and its cargo together.
Ubiquinol is the native mobile electron carrier between complexes in the respiratory chain, and methylene blue can act as an artificial carrier that bypasses part of it. They act on the same transport step by different routes.
The reductases that convert methylene blue to its leuco form are FAD or FMN dependent, and riboflavin is the precursor for both flavins. Flavin status therefore affects how quickly the dye is reduced inside the cell.
Reduced glutathione donates electrons to methylene blue and converts it to the leuco form. A large thiol dose in the same window shifts which state of the dye is present.
NAC supplies cysteine for glutathione synthesis, and glutathione reduces methylene blue to its colourless form. Raising thiol capacity therefore changes the dye's oxidation state balance.
The dihydrolipoate form of alpha lipoic acid is a strong reducing dithiol that can hand electrons to methylene blue. Co-dosing shifts the dye toward its reduced state rather than adding a separate effect.
Methylene blue inhibits soluble guanylate cyclase, the enzyme through which nitric oxide raises cyclic GMP in vascular smooth muscle. Dietary nitrate from beetroot works by increasing nitric oxide availability, so the two push the same signalling step in opposite directions. Anyone combining them for blood flow support is working against themselves at the level of the enzyme. This is a pharmacological expectation rather than a measured combination result.
Citrulline raises plasma arginine and supports normal nitric oxide production. Methylene blue blocks the downstream guanylate cyclase step that nitric oxide signals through. The opposition is at different points of one pathway, so the net effect depends heavily on dose and timing rather than being a simple cancellation.
Arginine is the substrate nitric oxide synthase uses to make nitric oxide. Methylene blue acts below that point by inhibiting soluble guanylate cyclase, the receptor enzyme for nitric oxide. Stacking them for vascular support is mechanistically incoherent, and the interaction is textbook rather than trial-derived.
Garlic preparations are used for circulatory support largely through nitric oxide dependent vasodilation. Methylene blue dampens the cyclic GMP response to nitric oxide. The expected result is a blunted garlic effect rather than an additive one, and no combination trial defines the size of that.
Activated charcoal binds methylene blue avidly, which is exactly why the dye is used as the reference adsorbate for carbon surface area testing. Taken in the same window, charcoal will hold methylene blue in the gut lumen and reduce how much reaches circulation. Separating the two by several hours is the usual formulation answer.
Methylene blue is a cationic dye and binds readily to the negatively charged interlayer of bentonite, a property used routinely to characterise clay adsorption capacity. Co-ingestion is expected to lower the amount available for absorption. This is a physical binding effect, not a metabolic one.
Under light, methylene blue is an efficient photosensitiser that generates singlet oxygen. Carotenoids including beta-carotene are among the most effective biological quenchers of singlet oxygen. Where methylene blue is being used for a redox purpose, a carotenoid load changes the oxidant environment it acts in, which is worth flagging in either direction.
Methylene blue is dose-dependent in its redox behaviour: low concentrations act as an electron carrier, higher ones cycle and can generate oxidant species. Alpha-tocopherol terminates lipid peroxidation chains in membranes. A membrane antioxidant therefore modifies the oxidant side of that curve without touching the electron-transport side.
Acetyl-l-carnitine supports transfer of fatty acyl groups into mitochondria for oxidation, feeding reducing equivalents into the respiratory chain. Methylene blue can accept electrons and pass them to cytochrome c, bypassing part of that chain. The two touch the same organelle from different ends, and no human study has tested them together.
Talk to a doctor before taking Methylene Blue if any of these apply to you: SSRI/Antidepressant Users, G6PD Deficiency, Pregnant/Nursing, High Blood Pressure. These are flags to check first, not effects Methylene Blue is known to cause.
Not medical advice. Show the label to your pharmacist.What Methylene Blue actually does.
Methylene blue is redox active and cycles between an oxidised blue form and the colourless reduced form, leucomethylene blue, which is why it behaves as an electron shuttle in biological systems.
In its reduced form it can accept electrons from NADH and pass them to cytochrome c, providing an alternative route into the terminal part of the mitochondrial respiratory chain.
Its redox effect is dose dependent and non-linear: at low concentrations it acts mainly as an electron carrier, while at higher concentrations it cycles and can itself generate oxidant species.
It is a reversible inhibitor of monoamine oxidase A, which is the basis of the well-known caution about combining it with anything that raises serotonin.
Where Methylene Blue comes from.
It is made in a chemical plant, not grown. The same blue molecule can be sold to a textile mill or held to a pharmacopoeial impurity specification, and the difference is how much cleaning-up and testing happened after the reaction, not the molecule itself.
Chemically synthesised. The molecule is identical to the one a plant or an animal makes, and building it deliberately means a known purity, a fixed dose and no crop contaminants. For several nutrients this is the only route that reaches a usable amount.
Production begins from dimethylaniline-type aromatic amines together with a sulfur source, all petrochemical-derived commodity chemicals.
Oxidation and sulfur incorporation build the tricyclic phenothiazine core, and the resulting thiazine dye is isolated as its chloride salt.
Crude dye carries residual metals and reaction by-products. Repeated recrystallisation and filtration steps are what separate a pharmacopoeial-grade lot from a dye-grade one; the two share a molecule and differ in what else is in the drum.
Pharmacopoeial material is released against stated assay and impurity limits with a certificate of analysis; dye-grade material is released against colour strength instead.
Supplied as dark green-blue crystals, usually the trihydrate, or pre-dissolved at a stated concentration.
The forms it comes in.
The essence, in one line each.
- A single low oral dose raised functional MRI activity during sustained-attention and short-term memory tasks and lifted correct answers on a memory-retrieval test by about 7 percent in healthy adults.Randomised trial. Rodriguez et al., 2016 (Radiology). PMID 27351678 ↗
- Across 11 randomised trials in 556 adults, methylene blue raised mean arterial pressure by about 8 mmHg and increased systemic vascular resistance, in line with its inhibition of the nitric oxide signalling that relaxes blood vessels.Meta-analysis. Pruna et al., 2023 (Journal of Cardiothoracic and Vascular Anesthesia). PMID 37880041 ↗
- An electrochemical sensor built on the ascorbate and dye redox couple, which documents that ascorbic acid reduces the oxidised dye form in solution; chemistry in a measurement cell, not a human result.In vitro study. Wan T et al., 2026 (Analytical chemistry). PMID 42307012 ↗
- A single hospital case describing methylene blue in a supervised clinical setting where haemoglobin iron was locked in the ferric state; it documents medical use and says nothing about supplemental intake.Case report. Miruzzi L et al., 2026 (BMJ case reports). PMID 41571394 ↗
- A paediatric case of low measured blood oxygen in which methylene blue was given under monitoring; useful only as documentation of hospital pharmacology and not as evidence for over-the-counter use.Case report. Nicolaus S et al., 2026 (Klinische Padiatrie). PMID 41554289 ↗
- A short clinical series in which methylene blue was used in a monitored oncology setting after a drug-induced change in haemoglobin iron state; it illustrates supervised medical use only.Case series. Sakach JC et al., 2026 (Gynecologic oncology reports). PMID 41694054 ↗
These are the studies our verdict leans on, chosen from the 578 we read for Methylene Blue. The full linked list is below.
The studies, linked.
9 sources behind our Methylene Blue verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
- Clinical trialEffectiveness and Safety of Methylene Blue for Prevention of Postoperative Neurocognitive Disorders in Patients Undergoing Pancreatic Tumor Surgery: A Prospective Randomized Controlled Clinical TrialClinicalTrials.gov ↗NA · 314 participants · Completed
- Clinical trialThe Effect of Intradermal Methylene Blue Application on Hemodynamic Stability Under General Anesthesia in Breast Surgery: A Prospective Observational StudyClinicalTrials.gov ↗220 participants · Completed
- Clinical trialInfrared Lymphangiography as a Method of Sentinel Node IdentificationClinicalTrials.gov ↗NA · 89 participants · Completed
- Clinical trialSensitivity of the Saline Load Test With and Without Methylene Blue Dye in the Diagnosis of Traumatic Knee ArthrotomiesClinicalTrials.gov ↗NA · 60 participants · Completed
- Clinical trialThe Clinical Trial of Methylene Blue Application Combined With Photodynamic Therapy for Treatment of SARS-CoV-2 Infected PatientsClinicalTrials.gov ↗PHASE1 · 60 participants · Completed
- Clinical trialEvaluation of Microaspiration and Efficacy of Above the Cuff Suctioning During General Anesthesia: A Comparison of Two Endotracheal Tubes With Suction Above Cuff With a Standard Endotracheal TubeClinicalTrials.gov ↗PHASE4 · 50 participants · Terminated
- Clinical trialOpen Label Randomized Controlled Trial Pharmacokinetic and Vitro Transmission Blocking Activities Study of Primaquine Compare to Methylene Blue in Healthy Volunteer Both G6PD Normal and G6PD DeficiencyClinicalTrials.gov ↗PHASE1 · 20 participants · Completed
- Clinical trialTreatment of Basal Cell Carcinoma (BCC) of the Skin, of the Morpheiform, Infiltrative, and Noduloulcerative Types in Inoperable Patients and Not Suitable for Radiotherapy Using Formulated Methylene BlueClinicalTrials.gov ↗PHASE3 · 20 participants · Enrolling by invitation
- Clinical trialThe Effect of Combination Therapy of Oral Methylene Blue and Platelet-rich Plasma-fibrin Glue in Patients With Non-healing Diabetic Foot Ulcer: a Pilot StudyClinicalTrials.gov ↗EARLY PHASE1 · 20 participants · Unknown
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Problems people have reported.
Read this carefully. These are 5,539 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Methylene Blue is, not how risky it is. A report is not proof Methylene Blue caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.